Parotid Gland Anatomy and Tumours — Relations, Nerves and Frey Syndrome

The parotid gland lies anterior and inferior to the ear, occupying the retromandibular region. It extends toward the zygomatic arch superiorly and the lower border of the mandible inferiorly. The masseter and mandibular ramus lie anteriorly, while sternocleidomastoid forms an important posterior relation. These landmarks explain why a swelling below the ear can arise from the parotid rather than the submandibular gland.

Parotid acini are predominantly serous, producing watery, enzyme-containing saliva. Myoepithelial cells surrounding the secretory units help expel that secretion, and the duct system modifies its electrolyte composition before it enters the mouth. The useful functional association is salivary production and the initial digestion of carbohydrate by amylase, rather than a mucous-dominant secretion.

The facial nerve divides the gland into superficial and deep surgical lobes. The superficial lobe lies lateral to the nerve and extends over the posterior masseter; the deep lobe lies medial to it. This is a surgical relation, not a statement that the facial nerve supplies the gland. Facial nerve preservation is central to benign parotid tumour surgery because its branches control the muscles of facial expression.

The external carotid supplies the gland and terminates as the superficial temporal and maxillary arteries. The retromandibular vein is formed by union of superficial temporal and maxillary venous drainage. These relationships are relevant when interpreting a vascular injury or a scan showing the position of a tumour. An anatomical landmark should not be treated as an infallible boundary because individual neurovascular arrangements vary.

The gland also contains lymph nodes. Skin malignancies of the face or scalp may spread to intraparotid or nearby nodes, so a parotid-region mass is not automatically a primary salivary neoplasm. Examination should consider the overlying skin, regional nodes and facial nerve function. A question describing an established scalp lesion plus a parotid mass may be testing regional metastatic drainage rather than glandular secretion.

Stensen duct leaves the anterior part of the superficial parotid lobe and crosses the surface of masseter. At the anterior border of masseter it turns medially, pierces buccinator and opens into the oral vestibule opposite the upper second molar. This course connects a gland beside the ear with a mucosal opening inside the cheek.

1. Identify the parotid gland in the retromandibular region.
2. Trace the duct forward across masseter.
3. At the anterior masseter border, follow its medial turn.
4. Identify penetration of buccinator and the opening opposite the maxillary second molar.

The muscle crossed superficially is masseter, while the muscle pierced is buccinator. These are common distractors because they occupy the same broad region. The opening is in the cheek vestibule, not on the floor of the mouth. The latter association belongs to the submandibular duct, so a question about a parotid duct opening must not be answered with the sublingual caruncle.

Pain and swelling related to meals suggest impaired salivary outflow or an inflammatory process. They should prompt examination of the duct and gland rather than an immediate assumption of neoplasm. Conversely, a persistent painless lump still requires assessment even when the duct opening is unremarkable; a tumour and a duct obstruction are different categories of parotid disease.

Begin in the inferior salivatory nucleus. Preganglionic parasympathetic fibres travel with the glossopharyngeal nerve, enter its tympanic or Jacobsen branch, participate in the tympanic plexus and continue as the lesser petrosal nerve. They synapse in the otic ganglion. Postganglionic fibres then travel with the auriculotemporal nerve, a branch of V3, to reach the parotid.

A fibre carried by a trigeminal branch need not originate in the trigeminal system. The auriculotemporal nerve is the final carrier of parotid parasympathetic fibres, but the secretomotor origin is CN IX. This distinction explains why questions asking for the nerve of origin, the ganglion or the final transporting branch can have different answers without contradiction.

Contrast this route with the facial parasympathetic pathway through chorda tympani to the submandibular ganglion and the submandibular and sublingual glands. The ear is involved in both routes, but the ganglion and target glands differ. This is a useful bridge between parotid anatomy and revision of the middle ear.

Pleomorphic adenoma is the commonest benign salivary gland neoplasm. It commonly arises in the superficial parotid lobe and presents as a slowly enlarging, usually painless mass. Its name refers to varied microscopic architecture: epithelial and myoepithelial components occur within a diverse stromal background. The term benign mixed tumour describes this appearance; it does not mean a mixture of benign and malignant cells.

Epithelial elements may form ducts, nests or trabeculae, while the stromal component can be myxoid or chondroid. In a microscopy stem, the combination of glandular or duct-like structures with a cartilage-like or myxoid background is more useful than any single descriptive adjective. Pleomorphic architecture is not itself evidence of aggressive malignant cytology.

The apparent capsule is a pseudocapsule, with variable thickness and microscopic tumour extensions beyond the gross boundary. Incomplete removal or simple shelling-out may leave residual tumour and lead to recurrence. This is why the surgical principle is complete excision with appropriate margins and preservation of the facial nerve when feasible, rather than assuming a visible capsule guarantees containment.

Treatment is selected according to location, size, relation to the facial nerve and surgical expertise. Superficial parotidectomy is a conventional operation for suitable superficial lesions, while selected benign lesions may be treated by carefully planned extracapsular dissection. Deep-lobe disease requires different exposure and planning. Do not turn the existence of a limited operation into a rule that every benign tumour should simply be enucleated.

Warthin tumour, also called papillary cystadenoma lymphomatosum, has a distinctive combination of oncocytic epithelium and lymphoid stroma. It is associated with smoking and can be multiple or bilateral. Bilaterality therefore supports this diagnosis in an appropriate stem, but histology and investigation remain important; it is not a substitute for clinical assessment.

Mucoepidermoid carcinoma is the classic answer to the commonest primary malignant major salivary gland tumour. Keep the anatomical denominator explicit: a statement about major glands should not be automatically extended to every minor-gland tumour series. Adenoid cystic carcinoma is associated with spread along nerves, and a relatively slow clinical course does not make that invasion benign.

Features suggesting malignancy include rapid growth, pain, fixation or skin tethering, ulceration, cervical lymphadenopathy and facial nerve weakness. No single absent feature excludes cancer. A painless lump with normal facial movements may still need imaging and tissue sampling. The purpose of the pattern table is to narrow a differential diagnosis, not to replace diagnostic evidence.

Assessment begins with duration, growth pattern, pain, meal-related change, previous tumours or surgery and relevant skin lesions. Examine the gland, duct opening, skin and neck nodes, and record facial nerve function before intervention. Pre-existing weakness is a malignancy clue and a necessary baseline for postoperative comparison.

1. Use ultrasound to characterise an accessible mass and assess nearby nodes.
2. Obtain fine-needle aspiration or other appropriately planned sampling when indicated; interpret cytology with the clinical picture.
3. Use MRI where deep-lobe extent, neighbouring structures or facial nerve relationships require definition.
4. Plan surgery according to diagnosis, glandular compartment and tumour extent, with facial nerve preservation where oncologically appropriate.
5. Explain complications including facial weakness, haematoma, salivary fistula and gustatory sweating.

FNA is a diagnostic aid, not an absolute guarantee that a lesion is benign. Imaging and cytology can be discordant, and further specialist evaluation may be needed. Unplanned incisional or excisional biopsy of a parotid mass risks complicating definitive treatment; the investigation route should be selected with its anatomical relations in mind.

For malignant disease, the extent of parotid surgery, need for neck treatment and use of radiotherapy depend on histology, grade, spread, margins and nerve involvement. A functioning facial nerve is preserved where feasible unless directly infiltrated. The correct exam principle is adequate oncological treatment balanced with preservation of function, not routine sacrifice of the nerve merely because it traverses the gland.

Frey syndrome is gustatory sweating and flushing in skin over the parotid region, usually after surgery or injury. Regenerating postganglionic parasympathetic fibres intended for salivary tissue aberrantly reach cutaneous sweat glands and vessels. A meal-related secretory signal therefore produces sweating and flushing in the skin instead of, or alongside, the intended salivary response.

Both normal salivary parasympathetic fibres and the autonomic fibres serving sweat glands use cholinergic signalling at their peripheral targets. This helps explain how misdirected regeneration can create a functional gustatory response in skin. The defining mechanism is aberrant reinnervation, not an infected wound or saliva leaking through the skin.

The Minor starch–iodine test maps sweating: iodine is applied to the skin, starch is added after drying, and gustatory stimulation causes a dark colour change in sweating areas. Patients with minimal symptoms may require reassurance. Troublesome symptoms can be treated with topical antiperspirants or anticholinergics, or intradermal botulinum toxin. The choice depends on symptom burden and specialist assessment.